The year in cardiology 2015: prevention

Eur Heart J. 2016 Feb 7;37(6):510-9. doi: 10.1093/eurheartj/ehv721. Epub 2016 Jan 3.

Authors

M John Chapman¹, Stefan Blankenberg², Ulf Landmesser³

Affiliations

¹ National Institute for Health and Medical Research (INSERM), Dyslipidemia and Atherosclerosis Research, Pitié-Salpêtrière University Hospital, Paris FR-75651, France University of Pierre and Marie Curie, Paris, France john.chapman@upmc.fr.
² Clinic for Cardiology, University Heart Center Hamburg, German Center for Cardiovascular Research (DZHK), Hamburg, Germany.
³ Department of Cardiology, Charité Universitätsmedizin Berlin (CBF), Berlin, Germany German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Berlin, Germany.

No abstract available

Publication types

Review

MeSH terms

Adrenocorticotropic Hormone / drug effects
Antibodies, Monoclonal / therapeutic use
Anticholesteremic Agents / therapeutic use
Biomarkers / blood
Cardiovascular Diseases / diagnostic imaging
Cardiovascular Diseases / prevention & control*
Cholesterol, LDL / drug effects
Diabetic Angiopathies / prevention & control
Disease Progression
Dyslipidemias / drug therapy
Global Health
Humans
Hydrocortisone
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hypercholesterolemia / prevention & control
Lipoprotein(a) / metabolism
PCSK9 Inhibitors
Plaque, Atherosclerotic / diagnostic imaging
Randomized Controlled Trials as Topic
Risk Assessment
Therapies, Investigational / adverse effects
Vitamin E / metabolism

Substances

Antibodies, Monoclonal
Anticholesteremic Agents
Biomarkers
Cholesterol, LDL
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipoprotein(a)
PCSK9 Inhibitors
Vitamin E
Adrenocorticotropic Hormone
PCSK9 protein, human
Hydrocortisone